Ophthotech Partners with UMass to Develop ‘Minigene’ Therapy for Retinal Disease

March 2, 2018: By Jon Swedien

Ophthotech and the University of Massachusetts have agreed to a gene therapy research collaboration that will focus on the school’s “minigene” therapy and will target retinal disease, the company announced Feb. 27.

The minigene approach is designed to deliver a shortened but functional form of a large gene packaged in a standard-size adeno-associated virus (AAV) delivery vector commonly used in gene therapy, Ophthotech said. The strategy may offer a solution for diseases difficult to treat through conventional AAV gene replacement therapy, the company said.

The partnership includes a series of sponsored research agreements with the university’s medical school and its Horae Gene Therapy Center. The research agreements will use the minigene therapy and other novel gene-delivery technologies, Ophthotech said.

As a condition of each research agreement, the university has granted Ophthotech an option to obtain an exclusive license to any patents or patent applications that result from the collaboration.

Ophthotech said professor Guangping Gao, PhD, and associate professor Hemant Khanna, PhD, will lead the collaboration. The company said Gao is a pioneer in the development of a novel AAV family for gene therapy and that Khanna’s research focuses on the molecular mechanism of inherited ocular disorders.

The deal could signify a new direction for Ophthotech, which until August 2017 had been developing Fovista. The proposed combination treatment for wet age-related macular degeneration failed in two Phase III trials in combination with Lucentis. It was among several heralded proposed combination treatments for retinal disease that failed in Phase III in 2017.

Need Deeper Analysis? Sign up for Market Scope's monthly newsletter to get in-depth coverage of the ophthalmic market, including quarterly procedure volumes based on survey data and meeting coverage from around the world.

Recent Ophthalmic News

CMS Allows Medicare Advantage Plans to Apply Step Therapy to Retinal Injections

Glaukos Reports Drug Collaboration with D. Western, Q2-2018 Net Sales Increase of 5 Percent

Allergan Will Co-develop Editas’ CRISPR Genome Editing Candidate for LCA10

Spark Reports Q2-2018 Net Sales of $4.3 Million for Luxturna

Aerie’s Rhopressa Posts $2.4 Million in Net Revenues in Q2-2018

Astellas Acquires Quethera, Glaucoma Gene Therapy Candidate in Potential $109 Million Deal

STAAR Surgical Completes $77.9 Million Public Offering

Rheon’s eyeWatch Adjustable Glaucoma Device Implanted in Three UK Patients

Carl Zeiss Meditec Revenues Total $356 Million in Third Quarter of FY2018, a 12.7 Percent Increase

Kedalion Therapeutics Raises $5 Million in Series A Financing

Second Sight Reports 17 Argus II Implantations in Q2-2018; Firm to Focus on Orion System

Iridex Revenues Grow 3 Percent in Q2-2018

Omeros Revenues Drop Steeply with Omidria’s Temporary Loss of Pass-through Status

Shire’s Xiidra Delivers $100 Million in Q2-2018 Revenues, an Increase of 75 Percent

STAAR Posts Q2-2018 Revenues of $33.9 Million, a 55 Percent Increase

Avedro Names Glaukos CEO Thomas Burns to its Board

Aerie Licenses DSM’s Bioerodible Implant Technology for Ophthalmic Use for $15 Million

Alimera’s Q2-2018 Revenues Increase 5 Percent

Presbyopia Therapies’ PRX Meets Phase IIb Endpoints

Clinical Study of Imprimis’ Dropless Formulation Set to Begin in Canada

Coming soon

2018 Ophthalmic Laser Report: A Global Market Analysis for 2017 to 2023 (Photocoagulation, Photodisruption, and SLT